Anti-inflammatory peptide from black-bone chicken and application of anti-inflammatory peptide

Abstract

The invention discloses an anti-inflammatory peptide from black-bone chicken and application thereof, and belongs to the field of biological medicine. The amino acid sequence of the anti-inflammatory peptide is as shown in SEQ ID NO. 2 or SEQ ID NO. 3. The anti-inflammatory peptide provided by the invention effectively solves the technical problems that active ingredients of a polypeptide mixture in the prior art are not clear, and standardized quality control and application are difficult to realize. Through combination of a virtual screening strategy and animal experiment verification, the two peptide fragments are proved to be capable of remarkably improving core symptoms of ulcerative colitis, including effective reduction of disease activity indexes, recovery of colon length, improvement of intestinal tract tissue pathological damage and adjustment of key pro-inflammatory / anti-inflammatory factor levels. The anti-inflammatory peptide provided by the invention has the potential advantages of natural sources, diversified targets and low side effect risk, provides important candidate molecules for developing safe and effective novel ulcerative colitis treatment medicines or functional foods, and has good clinical application prospects and industrialization values.

Description

Technical Field

[0001] This invention relates to the field of biomedicine, and in particular to an anti-inflammatory peptide derived from black-boned chicken and its applications. Background Technology

[0002] Ulcerative colitis is a chronic, relapsing inflammatory bowel disease with an incompletely understood etiology. Clinical treatment primarily relies on aminosalicylic acids, glucocorticoids, immunomodulators, and biologics. However, existing drugs generally suffer from single-target effects, significant side effects, and high treatment costs, limiting their long-term safety and accessibility. Therefore, developing novel therapeutic ingredients with good safety and proven efficacy is of significant clinical importance.

[0003] In recent years, food-derived bioactive peptides have become a hot topic in research on intestinal inflammation intervention due to their natural origin, high safety, and easy absorption. Existing studies have attempted to screen for peptides with anti-inflammatory activity from animal tissue hydrolysates; for example, hydrolyzed peptides from black-boned chicken liver have been reported to have the potential to improve ulcerative colitis. However, the active products obtained by current technologies are usually mixtures of multiple peptides, among which the key peptides that exert the specific efficacy remain unclear. The lack of identification of specific active ingredients makes it difficult to elucidate their mechanisms of action, hinders product quality control and standardized production, and limits their further application in drug development.

[0004] While virtual screening technology offers the potential for efficient and accurate identification of bioactive peptides, numerous challenges remain in practical applications. For instance, accurately identifying single peptides with specific physiological functions from complex peptide systems requires overcoming difficulties such as the complexity of peptide-target interaction prediction, the effectiveness of activity verification systems, and the reliability of cross-species in vivo functions. Therefore, how to achieve accurate identification of specific functional peptides from mixtures while preserving their natural structure-activity relationships, and further verify their in vivo activity, is a pressing technical problem to be solved in this field.

[0005] In summary, there is an urgent need in this field for a specific peptide with a well-defined sequence, high anti-inflammatory activity, and easy standardized preparation, in order to overcome the problems of unclear mixture composition, difficulty in quality control, and limited mechanism research in existing technologies. Summary of the Invention

[0006] The purpose of this invention is to provide an anti-inflammatory peptide derived from black-boned chicken and its applications, thereby addressing the problems existing in the prior art. This invention precisely identifies two specific anti-inflammatory peptides, LSGPIRFF and SDPWWKAF, from black-boned chicken liver hydrolysate, solving the problem of unclear active ingredients and difficulty in standardized application of polypeptide mixtures in the prior art. Experiments have confirmed that this peptide can significantly improve the core symptoms of ulcerative colitis, providing an important candidate molecule for the development of safe and effective new therapeutic drugs and functional foods.

[0007] To achieve the above objectives, the present invention provides the following solution:

[0008] This invention provides an anti-inflammatory peptide derived from black-boned chicken, the amino acid sequence of which is shown in SEQ ID NO.2.

[0009] The present invention also provides an anti-inflammatory peptide derived from black-boned chicken, the amino acid sequence of which is shown in SEQ ID NO.3.

[0010] The present invention also provides a method for preparing the anti-inflammatory peptide, comprising preparing the anti-inflammatory peptide by means of artificial solid-phase synthesis according to the amino acid sequence of the anti-inflammatory peptide.

[0011] The present invention also provides an application of the aforementioned anti-inflammatory peptide in the preparation of anti-inflammatory products.

[0012] Furthermore, the anti-inflammatory product includes anti-inflammatory drugs.

[0013] Furthermore, the anti-inflammatory drug is used for the prevention and / or treatment of ulcerative colitis.

[0014] The present invention also provides a medicament for the prevention and / or treatment of ulcerative colitis, the active ingredient of which includes the aforementioned anti-inflammatory peptide.

[0015] Furthermore, the drug also includes pharmaceutically acceptable carriers and excipients.

[0016] Furthermore, the dosage forms of the drug include tablets, capsules, and granules.

[0017] The present invention also provides a health product for the prevention of ulcerative colitis, the active ingredient of which includes the aforementioned anti-inflammatory peptide.

[0018] The present invention discloses the following technical effects:

[0019] This invention marks the first precise identification of two specific peptides, LSGPIRFF and SDPWWKAF, with well-defined sequences and highly effective anti-inflammatory activity from hydrolyzed peptides from black-boned chicken liver. This effectively solves the technical challenges of unclear active ingredients in peptide mixtures and difficulties in achieving standardized quality control and application in existing technologies. Through virtual screening combined with animal experiments, it was confirmed that these two peptides can significantly improve the core symptoms of ulcerative colitis, including effectively reducing the disease activity index, restoring colon length, improving intestinal tissue pathological damage, and regulating the levels of key pro-inflammatory / anti-inflammatory factors.

[0020] Compared with existing therapeutic drugs, the anti-inflammatory peptides provided by this invention have the potential advantages of being naturally sourced, having diverse targets, and having a low risk of side effects. They provide important candidate molecules for the development of safe and effective new drugs or functional foods for the treatment of ulcerative colitis, and have good clinical application prospects and industrialization value. Attached Figure Description

[0021] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0022] Figure 1 This represents the intersection of potential targets for anti-inflammatory peptides and therapeutic targets for ulcerative colitis.

[0023] Figure 2 PPI network diagram of intersection target points;

[0024] Figure 3 Colon length in UC mice under different treatment groups;

[0025] Figure 4 Colonic injury in UC mice under different treatment groups;

[0026] Figure 5 The serum levels of inflammatory factors IL-6 (A), TNF-α (B), IL-1β (C), and IL-10 (D) in UC mice under different treatment groups were measured. Detailed Implementation

[0027] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as a limitation of the present invention, but rather as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0028] It should be understood that the terminology used in this invention is merely for describing particular embodiments and is not intended to limit the invention. Furthermore, with respect to numerical ranges in this invention, it should be understood that each intermediate value between the upper and lower limits of the range is also specifically disclosed. Any stated value or intermediate value within a stated range, as well as each smaller range between any other stated value or intermediate value within said range, is also included in this invention. The upper and lower limits of these smaller ranges may be independently included or excluded from the range.

[0029] Unless otherwise stated, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. While only preferred methods and materials have been described herein, any methods and materials similar or equivalent to those described herein may be used in the implementation or testing of this invention. All references to this specification are incorporated by way of citation to disclose and describe methods and / or materials associated with those references. In the event of any conflict with any incorporated reference, the content of this specification shall prevail.

[0030] Various modifications and variations can be made to the specific embodiments described in this specification without departing from the scope or spirit of the invention, as will be apparent to those skilled in the art. Other embodiments derived from this specification will also be apparent to those skilled in the art. This specification and embodiments are merely exemplary.

[0031] The terms “include,” “including,” “have,” “contain,” etc., used in this article are all open-ended terms, meaning that they include but are not limited to.

[0032] The inventors previously obtained a hydrolyzed peptide from black-boned chicken liver using alkaline protease, which was documented in Chinese invention patent CN119979649B. Based on this, the inventors screened and obtained two anti-inflammatory peptides with effects on improving ulcerative colitis. First, the activity scores of the deduplicated peptides were predicted using the PeptideRanker, ToxinPred, PreAIP, ProIn-Fuse, and AnOxPePred databases. The SwissTargetPrediction and PharmMapper databases were used to predict potential targets for the anti-inflammatory peptides. The GeneCards, Drugbank, OMIM, and TTD databases were used to search for relevant targets for ulcerative colitis. The intersection of the potential targets of the peptides with therapeutic targets for ulcerative colitis was obtained using the MicroBioInformatics online website. The intersection targets were analyzed using the STRING database and Cytoscape 3.10 software to obtain the core targets. AutoDock Vina software was used to dock peptides with core targets, and the docking results were viewed using Pymol software. After identifying potential anti-inflammatory peptides, peptides were artificially synthesized to verify their effect in improving ulcerative colitis. Details are shown below:

[0033] Example

[0034] I. Experimental Methods

[0035] 1. Screening of anti-inflammatory peptides derived from black-boned chicken

[0036] (1) Peptide sequence library construction: The black chicken liver hydrolysate obtained from the Chinese invention patent with announcement number CN119979649B was used as the source. After mass spectrometry identification and deduplication, 2428 unique peptide sequences were obtained to construct the initial peptide sequence library.

[0037] (2) Bioactivity Prediction: The activity score of peptides was predicted in the PeptideRanker database (http: / / distilldeep.ucd.ie / PeptideRanker / ), and peptides with a score greater than 0.9 were screened. The toxicity of peptides was predicted in the ToxinPred database (http: / / crdd.osdd.net / raghava / toxinpred / ). The anti-inflammatory activity of peptides was predicted in the PreAIP database (http: / / kurata14.bio.kyutech.ac.jp / PreAIP / ). The pro-inflammatory activity of peptides was predicted in the ProIn-Fuse database (http: / / kurata14.bio.kyutech.ac.jp / ProIn-Fuse / ), which indirectly verified their anti-inflammatory activity. The antioxidant activity of peptides was predicted in the AnOxPePred database (https: / / services.healthtech.dtu.dk / services / AnOxPePred-1.0 / ).

[0038] 2. Target prediction and molecular docking

[0039] (1) Acquisition of anti-inflammatory peptide targets

[0040] The SMILES numbers of the anti-inflammatory peptides were obtained using the SwissADME tool in the SwissTargetPrediction database (https: / / swisstargetprediction.ch / ). In the SwissTargetPrediction interface, the SMILES number of the obtained peptide was entered, and Homo sapiens was selected as the species to perform target prediction.

[0041] The screened anti-inflammatory peptides were used to draw their molecular structures in ChemDraw software, and their 3D structures were obtained using the Chem3D plugin. The energy minimization of the peptide's 3D structure was performed using the computational tools in the Chem3D plugin. After completion, the structures were saved in pdbqt, *.sdf, and *.sd formats.

[0042] Upload the peptide's *.sdf file to the PharmMapper database (https: / / www.lilab-ecust.cn / pharmmapper / index.html). Set the parameters to Generate Conformers: yes; Maximum Generated Conformations: 300; Select Targets Set: Human Protein Targets Only (v2010, 2241) to predict targets. After the prediction run is complete, download the corresponding table and obtain the UniProt ID number. Search for the gene name corresponding to the UniProt ID number in the UniProt database (https: / / www.uniprot.org / ).

[0043] By merging the prediction results from the SwissTargetPrediction and PharmMapper databases and removing duplicates, a set of potential targets for anti-inflammatory peptides was obtained.

[0044] (2) Target acquisition for ulcerative colitis (UC)

[0045] Using "Ulcerative colitis" as the keyword, we searched the GeneCards (https: / / www.genecards.org), DrugBank (https: / / go.drugbank.com / ), OMIM (https: / / www.omim.org), and TTD (https: / / db.idrblab.net / ttd / ) databases to obtain UC-related targets. After integration and deduplication, we obtained a set of UC disease targets.

[0046] (3) Acquisition of the core target of anti-inflammatory peptides and UC

[0047] Upload anti-inflammatory peptide targets and UC disease-related targets to the Bioinformatics online website (https: / / www.bioinformatics.com.cn / static / others / jvenn / ) to obtain overlapping targets.

[0048] Import the intersecting target points into the STRING database (https: / / string-db.org / ), analyze the target information, and export TSV format files. Analyze the TSV files in Cytoscape 3.10 software, remove free target points, analyze the network graph in the toolbar, and finally select target points with a degree value greater than 40 as core targets. Based on the Uniprot ID number of the core targets, search on the Uniprot website, select protein structures with relatively complete structures and high resolution, and download PDB format files.

[0049] (4) Molecular docking verification of anti-inflammatory peptides and core targets

[0050] In PyMOL software, small molecule ligands and water were removed from the core target protein, and the data was saved as a PDB file. In Autodock Vina software, hydrogenation and charge calculations were performed on the peptide and core target, and docking was performed to check their binding energy. The data was then exported as a PDBQT file, and the docking results were viewed using PyMOL software.

[0051] 3. Peptide synthesis

[0052] The selected peptides were synthesized by Nanjing Peptide Industry Co., Ltd. using solid-phase synthesis, and all had a purity >95%.

[0053] 4. Animal experiments to verify

[0054] (1) Laboratory animals and grouping

[0055] Seventy male C57BL / 6 mice (6-8 weeks old) were randomly divided into seven groups (n=10) after acclimatization for 7 days: normal control group (NC), model group (DSS), positive control group (5-ASA), low-dose LSGPIRFF group (LSGL), high-dose LSGPIRFF group (LSGH), low-dose SDPWWKAF group (SDPL), and high-dose SDPWWKAF group (SDPH).

[0056] (2) Modeling and Intervention

[0057] The NC group received pure water throughout the treatment, while the other groups received free access to 2.5% (w / v) DSS solution for 12 days to establish the UC model. Simultaneously, gavage intervention was administered. Specific protocols are shown in Table 1. Mouse weight, fecal morphology, and fecal blood loss were recorded daily, and the Disease Activity Index (DAI) was calculated according to the criteria in Table 2.

[0058] Table 1 Mouse grouping scheme

[0059]

[0060] (3) Sample collection and processing

[0061] After the intervention, blood was collected in 2.0 mL centrifuge tubes via tail vein sampling. After incubating in a 37°C water bath for 1 h, the tubes were incubated at 4°C for 2 h. The supernatant was collected at 3000 r / min to obtain serum, which was then aliquoted and stored at -80°C for later use. The euthanized mice were dissected, and the intact colon tissue was removed, along with the surface fascia. The colon length was measured on cardstock and photographed for recording.

[0062] (4) Mouse disease activity index score

[0063] After modeling began, the Disease Activity Index (DAI) score was calculated based on the daily recorded mouse weight, fecal morphology, and degree of blood in the stool. Detailed scoring rules are shown in Table 2.

[0064] Mouse weight loss rate (%) = [(W x -W0) / W0]×100%,

[0065] DAI = (weight loss rate score + stool morphology score + bloody stool score) / 3.

[0066] Note: W x W0: Daily mouse body weight during administration; W0: Mouse body weight on the first day of administration.

[0067] Table 2 DAI Scoring Criteria

[0068]

[0069] (5) Pathological evaluation

[0070] Colonic tissue from the terminal cecum to the anterior end of the anus in mice of the NC, DSS, 5-ASA, LSGL, LSGH, SDPL, and SDPH groups was collected and fixed in 4% paraformaldehyde solution for 24 h. The tissue was then subjected to the following steps: dehydration, clearing, paraffin embedding, trimming, sectioning, dewaxing, hematoxylin staining, differentiation, eosin staining, dehydration, clearing, and mounting with neutral resin. The sections were observed under a microscope, and the degree of tissue damage was evaluated.

[0071] (6) Detection of mouse serum markers

[0072] Using mouse serum as the material, the concentrations of inflammatory factors were detected according to the instructions of the IL-6, TNF-α, IL-1β, and IL-10 ELISA kits. 100 μL of different concentrations of standards and serum samples were added to each well of a 96-well plate, and the plates were incubated at 37°C in the dark for 1.5 h. After washing three times with washing buffer, 100 μL of biotinylate antibody working solution was added, and the plates were incubated at 37°C in the dark for 1 h. After washing three times with washing buffer, 100 μL of 1×SA-HRP working solution was added, and the plates were incubated at 37°C in the dark for 30 min. After washing four times, 50 μL of chromogenic solution A was added, followed by 50 μL of chromogenic solution B, and the plates were incubated in the dark for 15 min. At the end of the reaction, 50 μL of stop solution was quickly added, and the mixture was thoroughly mixed. The absorbance was measured at 450 nm using a microplate reader.

[0073] II. Experimental Results

[0074] 1. Virtual Filtering Results

[0075] This invention utilizes the PeptideRanker database to score and predict the activity of 2428 peptides in BLP. Higher scores indicate a greater probability of peptide activity. Fifty peptides with scores greater than 0.9 were identified, and the top 20 were selected for further analysis. To assess the potential toxicity of the peptides, the ToxinPred database was used for prediction, and the results showed no toxicity. Anti-inflammatory and pro-inflammatory activities of the 20 peptides were predicted. The results showed that three peptides had anti-inflammatory activity scores exceeding 0.468: SGPIRFF (SEQ ID NO.1), SDPWWKAF (SEQ ID NO.2), and LSGPIRFF (SEQ ID NO.3). Simultaneously, the pro-inflammatory activity scores of these three peptides were 0.169, 0.116, and 0.201, respectively, all below 0.342, indicating low confidence (Table 3).

[0076] Table 3. Top 20 peptides predicted by PeptideRanker database

[0077]

[0078] 2. Target prediction and molecular docking results

[0079] This invention, by taking the intersection of screening potential anti-inflammatory targets and ulcerative colitis targets, found a total of 298 overlapping targets. Figure 1Intersection targets were analyzed in the STRING database. After filtering by a minimum interaction score of 0.7, 297 targets were obtained. PPI network analysis revealed that these 297 targets had a total of 1473 edges, averaging 9.92 edges per target, with an average local clustering coefficient of 0.478. The final exported TSV file was further analyzed in Cytoscape 3.10 software. After removing detached targets, the core targets with a degree value greater than 40 were SRC, EGFR, AKT1, HSP90AA1, ESR1, PIK3R1, and GRB2. Figure 2 ).

[0080] Download the PDB structure files of the seven core targets: SRC (PDB ID: 1FMK), EGFR (PDB ID: 3POZ), AKT1 (PDB ID: 8UW9), HSP90AA1 (PDB ID: 7RY0), ESR1 (PDB ID: 6OWC), PIK3R1 (PDB ID: 5M6U), and GRB2 (PDB ID: 8DGO). Analyze the binding of the three anti-inflammatory peptides to the core targets using Autodock Vina software. Molecular docking results show that the binding energies of LSGPIRFF with SRC, EGFR, AKT1, ESR1, PIK3R1, and GRB2 are -9.6, -7.6, -10.4, -6.3, -9.3, and -6.7 kcal / mol, respectively; the corresponding binding energies for SDPWWKAF are -7.3, -6.0, -9.3, -7.3, -7.7, and -7.8 kcal / mol (Table 4). Among them, SRC, EGFR, and AKT1 are involved in inflammatory signal transduction and epithelial barrier repair; ESR1 and PIK3R1 regulate immune homeostasis and mucosal barrier function; and GRB2 is involved in signal transduction and inflammatory response. Molecular docking results showed that LSGPIRFF and SDPWWKAF bind more stably to the core target, suggesting that they may exert anti-inflammatory effects by regulating inflammatory pathways and enhancing the intestinal barrier. Based on binding energy and target function, LSGPIRFF and SDPWWKAF were artificially synthesized and in vivo mouse experiments were conducted to verify whether they have the effect of improving ulcerative colitis (UC).

[0081] Table 4 Binding energy of anti-inflammatory peptides to core targets

[0082]

[0083] 3. Animal experiment verification results

[0084] (1) DAI score and weight change

[0085] This invention preliminarily determined the effects of synthetic peptides on UC mice by measuring the rate of weight change and DAI score. Results showed that the NC group had a weight change rate of 11.33%±3.50% and a DAI score of 0, significantly different from other groups. The DSS group had a weight change rate of -24.17%±2.64% and a DAI score of 3.78±0.17, significantly different from the NC group, indicating successful construction of the inflammatory pathological model. The 5-ASA group (weight change rate -14.33%±6.47% and DAI score 1.00±1.03) showed significant improvement in both indicators compared to the DSS group; however, it still showed a significant difference compared to the NC group, and its overall effect was weaker than that of anti-inflammatory peptides. Compared to the DSS group, all anti-inflammatory peptide intervention groups significantly reduced the DAI score. Among them, SDPWWKAF was more effective than LSGPIRFF, and high-dose intervention with the same peptide was superior to low-dose intervention. The high-dose SDPWWKAF (SDPH group) showed the best effect, with a weight change rate of -3.00%±6.81% and a DAI score that decreased to 0.78±0.86, close to the normal level (Table 5).

[0086] Table 5. Effects of anti-inflammatory peptides on mouse body weight, DAI score, and colon length.

[0087]

[0088] (2) Colon length

[0089] The colon length of mice in the NC group was 7.33±0.54 cm, indicating that the colon of mice in the NC group was healthy and undamaged under normal conditions. Compared with the NC group, the colon length of mice in the DSS group was only 3.78±0.22 cm, a reduction of 48.43%, indicating that DSS successfully induced and established an ulcerative colitis model. The colon length of mice in the 5-ASA group was 6.65±0.40 cm, which was significantly increased compared with the DSS group, but still significantly shorter than the NC group, indicating that 5-ASA has a certain ameliorative effect on UC, but cannot completely restore it to the normal level. The colon lengths of the LSGL group, LSGH group, SDPL group, and SDPH group were 5.15±0.16 cm, 5.40±0.30 cm, 5.58±0.47 cm, and 5.69±1.12 cm, respectively (Table 5). Figure 3 The colon lengths of the UC mice were significantly longer than those of the DSS group, indicating that they could indeed improve the symptoms of colonic shortening. The improvement effect of SDPWWKAF was stronger than that of LSGPIRFF, and the improvement effect of high-dose allopeptides was stronger than that of low-dose. The high-dose SDPWWKAF (SDPH group) showed the best effect and the longest colon length.

[0090] (3) Histopathology

[0091] The mucus layer is the most extensive layer in the body that comes into contact with the intestinal lumen environment and is the first line of defense of the intestinal mucosal barrier. In the NC group, the intestinal wall and mucosal layer were thicker, the crypt structure was intact, goblet cells were clear, and no inflammatory cell infiltration was observed. In the DSS group, the intestinal wall of mice was thinner, the lumen was larger, the mucosal layer was thinner, the crypt structure was extensively destroyed, the number of goblet cells was significantly reduced, and more severe inflammatory cell infiltration was observed. In the 5-ASA group, the intestinal wall and mucosal layer were thinner, but the intestinal lumen was smaller and the inflammatory infiltration was milder. Compared with the DSS group, the LSGL and LSGH groups showed more intact colonic crypt structure, more goblet cells, and milder inflammatory cell infiltration, with LSGL showing better results. The SDPL and SDPH groups showed similarities in colonic crypt structure integrity, goblet cell count, and degree of inflammatory infiltration to the NC group, with the SDPH group showing thicker intestinal wall and mucosal layer. Furthermore, compared with the 5-ASA group, SDPL and SDPH showed more significant effects in alleviating UC symptoms in mice. Figure 4 The above results indicate that LSGL, LSGH, SDPL, and SDPH can all alleviate the symptoms of UC in mice, with SDPH showing the best effect, approaching normal levels.

[0092] (4) Serum inflammatory factors

[0093] To investigate the effects of anti-inflammatory peptides on the levels of factors in the serum of mice with ulcerative colitis, this invention used an ELISA kit to detect the levels of IL-6, TNF-α, IL-1β, and IL-10. The results are as follows: Figure 5 As shown in the figure. Overall results indicated that DSS induction significantly promoted the secretion of pro-inflammatory factors, while anti-inflammatory drugs or anti-inflammatory peptide interventions alleviated this response to varying degrees. Compared with the NC group, the serum levels of pro-inflammatory factors IL-6, TNF-α, and IL-1β were significantly increased in the DSS group. After 5-ASA intervention, the levels of IL-6, TNF-α, and IL-1β were significantly decreased, with IL-6 and TNF-α levels approaching those of the NC group. Compared with the DSS group, LSGPIRFF supplementation significantly reduced the serum levels of IL-6, TNF-α, and IL-1β in mice. Compared with the LSGL group, TNF-α and IL-6 levels were higher in the LSGH group, indicating that LSGPIRFF can alleviate the inflammatory response in mice, but there was no significant dose difference. Compared with the DSS group, SDPWWKAF supplementation significantly reduced the levels of IL-6, TNF-α, and IL-1β in the SDPL and SDPH groups, and these levels were close to those of the NC group, with no significant dose difference. Furthermore, compared with LSGPIRFF supplementation, SDPWWKAF supplementation resulted in lower levels of pro-inflammatory factors in mice, which were closer to normal levels, suggesting that it had a more significant effect in improving UC in mice.

[0094] As demonstrated by the above examples, the two specific anti-inflammatory peptides, LSGPIRFF and SDPWWKAF, obtained through virtual screening from black-boned chicken liver hydrolysate peptides, have been shown in mouse inflammation model experiments to significantly improve symptoms of DSS-induced ulcerative colitis in mice, including reducing DAI scores, restoring colon length, improving histopathological damage, and regulating serum inflammatory factor levels. These peptides can be used to prepare drugs or functional foods for the prevention and / or treatment of ulcerative colitis.

[0095] The embodiments described above are merely preferred embodiments of the present invention and are not intended to limit the scope of the present invention. Various modifications and improvements made by those skilled in the art to the technical solutions of the present invention without departing from the spirit of the present invention should fall within the protection scope defined by the claims of the present invention.

Claims

1. An anti-inflammatory peptide derived from a hen, characterized in that, The amino acid sequence of the anti-inflammatory peptide is shown as SEQ ID NO.

2.

2. An anti-inflammatory peptide derived from a hen, characterized in that, The amino acid sequence of the anti-inflammatory peptide is shown as SEQ ID NO.

3.

3. A method of preparing an anti-inflammatory peptide as claimed in claim 1 or 2, characterized in that, The anti-inflammatory peptide is prepared by artificial solid-phase synthesis according to the amino acid sequence of the anti-inflammatory peptide.

4. Use of the anti-inflammatory peptide according to claim 1 or 2 in the preparation of an anti-inflammatory product.

5. Use according to claim 4, characterized in that, The anti-inflammatory product comprises an anti-inflammatory drug.

6. Use according to claim 5, characterized in that, The anti-inflammatory drug is used for preventing and / or treating ulcerative colitis.

7. A medicament for preventing and / or treating ulcerative colitis, characterized by, The active ingredient comprises the anti-inflammatory peptide according to claim 1 or 2.

8. The medicament according to claim 7, characterized in that, The drug further comprises a pharmaceutically acceptable carrier and excipient.

9. The medicament according to claim 7, characterized in that, The dosage form of the drug comprises tablets, capsules and granules.

10. A health care product for preventing ulcerative colitis, characterized by, The active ingredient comprises the anti-inflammatory peptide according to claim 1 or 2.

Images